Statera Biopharma, Inc. Common Stock
STAB
STAB was delisted on the 11th of January, 2023.
35 hedge funds and large institutions have $3.32M invested in Statera Biopharma, Inc. Common Stock in 2014 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 9 reducing their positions, and 6 closing their positions.
10% less funds holding
Funds holding: 39 → 35 (-4)
39% less capital invested
Capital invested by funds: $5.45M → $3.32M (-$2.13M)
44% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 9
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
93% less call options, than puts
Call options by funds: $1K | Put options by funds: $14K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.49M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$20.3K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$14.4K |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$12.8K |
| 5 |
Citigroup
New York
|
+$7.95K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PGCM
Prescott Group Capital Management
Tulsa,
Oklahoma
|
-$750K |
| 2 |
GIG
Goodnow Investment Group
Darien,
Connecticut
|
-$656K |
| 3 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
-$184K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$135K |
| 5 |
Renaissance Technologies
New York
|
-$32.3K |
STAB Hedge Fund Activity: Q1 2014 in Review
35 of the 3,463 institutional investors tracked by Wall St. Rank reported a position in Statera Biopharma, Inc. Common Stock (STAB) for Q1 2014, worth a combined $3.32M — down 39% from $5.45M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of STAB and 2 opened new positions — a net loss of 4 holders — while 9 trimmed existing stakes and 5 added.
The largest buyer was Sabby Management, opening a new position worth an estimated $1.49M. The largest seller was Prescott Group Capital Management, exiting entirely with an estimated $750K sold.
- 35 institutional investors held Statera Biopharma, Inc. Common Stock (STAB) as of Q1 2014, down from 39 in Q4 2013.
- Funds reported $3.32M of Statera Biopharma, Inc. Common Stock stock for Q1 2014, down 39% quarter-over-quarter.
- 2 funds opened new Statera Biopharma, Inc. Common Stock positions in Q1 2014 and 6 closed out, a net change of -4 holders.
- The largest Statera Biopharma, Inc. Common Stock buyer in Q1 2014 was Sabby Management, an estimated $1.49M added.
- The largest Statera Biopharma, Inc. Common Stock seller in Q1 2014 was Prescott Group Capital Management, an estimated $750K sold.
Based on aggregated 13F filings for Q1 2014.